SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

ordastobart

INBX·Inhibrx Biosciences, Inc.
BULLISH
Drug Impact Rating5/10
Trial phase
Phase 2 (Phase 2/3 HexAgon-HN study)
Time to market
If the Phase 2 expansion data supports accelerated approval discussions, a BLA filing could follow in 2027-2028, with potential approval in 2028-2029 for HNSCC. The Phase 3 portion of the HexAgon-HN study is already ongoing.
Why 5/10
The next hard catalyst for ordastobart is the Phase 2 expansion readout in HNSCC expected mid-2027 (~7 months away), which is a non-pivotal expansion cohort readout at a company that also has ozekibart (INBRX-109) with an April 2027 PDUFA date, limiting the binary impact of this single drug.
Actionable Insight BULLISH

Watch for the Phase 2 expansion readout in HNSCC expected mid-2027, which will show whether the strong Phase 2 interim data (48.3% cORR, 9.6-month PFS) holds in a larger cohort. Positive data could support accelerated approval discussions; negative data would undercut the pipeline thesis. Also monitor the ozekibart PDUFA date of April 14, 2027, which is the company's nearer-term binary catalyst.

Price Chart

Loading chart...

Executive Summary

Ordastobart (INBRX-106) is Inhibrx Biosciences' hexavalent OX40 agonist immunotherapy in Phase 2/3 development for first-line head and neck squamous cell carcinoma (HNSCC) and Phase 1/2 for perioperative non-small cell lung cancer (NSCLC). In September 2026, the randomized Phase 2 HexAgon study showed ordastobart plus pembrolizumab nearly doubled the confirmed objective response rate (48.3% vs 26.5%) and achieved 9.6-month median progression-free survival versus pembrolizumab alone, making it the first OX40 agonist to demonstrate clinical benefit in a randomized trial. The drug was also presented at ESMO 2026. The next catalyst is the Phase 2 expansion readout in HNSCC expected mid-2027, with a Phase 1/2 NSCLC readout also expected around the same time. Inhibrx trades at $83.30 with a $1.33B market cap, $199.5M cash, and $276.7M debt, with analyst consensus strongly bullish (8 Buy/Strong Buy, mean target $266.67).

How It Works

Ordastobart is a lab-designed antibody-like molecule that activates OX40, a protein on the surface of immune T-cells. By turning on OX40, it stimulates T-cells to multiply and attack cancer cells more aggressively. It is given in combination with pembrolizumab (Keytruda), a PD-1 checkpoint inhibitor, to boost the immune response against head and neck and lung cancers.

Trial Status

The randomized Phase 2 portion of the HexAgon-HN study in first-line HNSCC met its primary endpoint in September 2026, showing a 48.3% cORR and 9.6-month median PFS for ordastobart plus pembrolizumab. The Phase 2 expansion cohort is enrolling, with initial readout expected mid-2027. A Phase 1/2 study in perioperative NSCLC is also ongoing with results expected mid-2027. Data was presented at ESMO 2026.

The Two-Sided Case

▲ Bull Case4
First OX40 agonist to demonstrate clinical benefit in a randomized study, nearly doubling response rate (48.3% vs 26.5%) and showing 9.6-month median PFS vs pembrolizumab alone in first-line HNSCC.
CEO Mark Lappe has been consistently buying shares on the open market in Sept-Oct 2026, investing over $1.8M at prices around $84-$102, signaling insider confidence.
Analyst consensus is strongly bullish: 8 Buy/Strong Buy vs 2 Hold, with a mean price target of $266.67 implying ~220% upside from the $83.30 close.
Institutional holders include Morgan Stanley ($132M), BlackRock ($82M), and State Street ($57M); Citigroup doubled its position in Q3 2026.
▼ Bear Case4
OX40 agonist drug class has a history of clinical failures; INBRX-106 is the first to show positive randomized data but the sample is still small and durability unproven.
Phase 2 expansion and NSCLC readouts are not expected until mid-2027, leaving a long period with no near-term binary catalyst for this specific drug.
Inhibrx has $276.7M in long-term debt against $199.5M cash, burning ~$39M/quarter, creating potential dilution risk before any commercial revenue.
The stock already trades at a $1.33B market cap with no approved products; any clinical setback for ordastobart or ozekibart would cause severe downside.

Upcoming Catalysts

  • Phase 2 expansion readout in HNSCC expected mid-2027
  • Phase 1/2 perioperative NSCLC results expected mid-2027
  • Potential accelerated approval discussions if expansion data remains strong

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Inhibrx Biosciences, Inc. PRESS-RELEASE INBX ·Originating report

Sources · 10

Hover a chip for the title
1 prnewswire.com2 prnewswire.com3 prnewswire.com4 fiercebiotech.com5 cancernetwork.com6 markets.ft.com7 seekingalpha.com8 streetinsider.com9 healio.com10 sec.gov